Chief Operating Officer Alan Raffensperger to leave Sobi™

Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces that the company and Alan Raffensperger, Chief Operating Officer (COO), have come to the agreement that Alan Raffensperger will leave the company to pursue other opportunities.

Alan Raffensperger has led the commercial organisation responsible for launching Sobi’s haemophilia products in Europe as well as the expansion of Sobi’s global brands Orfadin and Kineret in Europe and North America. In addition to leading the commercial teams, Alan Raffensperger has also been responsible for Sobi's Partner Products business area, including the strategic process regarding the positioning of this business area.

“We thank Alan for his excellent leadership and dedication which has helped to evolve Sobi’s strong patient oriented commercial organisation into a highly skilled international team,” says Guido Oelkers, CEO and President of Sobi, on behalf of the Executive Leadership Team and the entire Sobi organisation.

----

About Sobi™

Sobi™ is an international speciality healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of speciality and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2016, Sobi had total revenues of SEK 5.2 billion (USD 608 M) and approximately 760 employees. The share (STO:SOBI) is listed on Nasdaq Stockholm. More information is available at www.sobi.com.

Swedish Orphan Biovitrum AB
Postal address SE-112 76 Stockholm, Sweden
Phone: 46 8 697 20 00     www.sobi.com